2018 SIGN国家临床指南:冠心病心律失常(152)

2018-09-20 苏格兰校际指南网络 SIGN官网

2018年9月,苏格兰校际指南网络(SIGN)发布了冠心病心律失常指南,冠心病与多种心律失常相关,急性冠脉综合征期间常见心律失常,室性心律失常是心跳骤停和心脏性猝死的主要原因,慢性冠心病患者,尤其是左心功能不全以及心力衰竭患者也有长期室性心律失常以及心脏性猝死的风险,本文主要针对冠心病相关心跳骤停和心律失常的关提供循证指导建议。

中文标题:

2018 SIGN国家临床指南:冠心病心律失常(152)

英文标题:

A national clinical guideline-SIGN 152 • Cardiac arrhythmias in coronary heart disease

发布机构:

苏格兰校际指南网络

发布日期:

2018-09-20

简要介绍:

2018年9月,苏格兰校际指南网络(SIGN)发布了冠心病心律失常指南,冠心病与多种心律失常相关,急性冠脉综合征期间常见心律失常,室性心律失常是心跳骤停和心脏性猝死的主要原因,慢性冠心病患者,尤其是左心功能不全以及心力衰竭患者也有长期室性心律失常以及心脏性猝死的风险,本文主要针对冠心病相关心跳骤停和心律失常的关提供循证指导建议。 

拓展指南:冠心病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 SIGN国家临床指南:冠心病心律失常(152))] GetToolGuiderByIdResponse(projectId=1, id=eb8ba1c0016a611c, title=2018 SIGN国家临床指南:冠心病心律失常(152), enTitle=A national clinical guideline-SIGN 152 • Cardiac arrhythmias in coronary heart disease, guiderFrom=SIGN官网, authorId=null, author=, summary=2018年9月,苏格兰校际指南网络(SIGN)发布了冠心病心律失常指南,冠心病与多种心律失常相关,急性冠脉综合征期间常见心律失常,室性心律失常是心跳骤停和心脏性猝死的主要原因,慢性冠心病患者,尤其是左心功能不全以及心力衰竭患者也有长期室性心律失常以及心脏性猝死的风险,本文主要针对冠心病相关心跳骤停和心律失常的关提供循证指导建议。 , cover=, journalId=null, articlesId=null, associationId=112, associationName=苏格兰校际指南网络, associationIntro=sign为苏格兰的国家健康体系提供基于证据的临床实践指南。这些指南产生于科学文献的系统评价,并且作为加快知识转化为行动力的工具。, copyright=0, guiderPublishedTime=Thu Sep 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年9月,苏格兰校际指南网络(SIGN)发布了冠心病心律失常指南,冠心病与多种心律失常相关,急性冠脉综合征期间常见心律失常,室性心律失常是心跳骤停和心脏性猝死的主要原因,慢性冠心病患者,尤其是左心功能不全以及心力衰竭患者也有长期室性心律失常以及心脏性猝死的风险,本文主要针对冠心病相关心跳骤停和心律失常的关提供循证指导建议。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>冠心病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=6ab761c0016a3202" title="血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018)" target=_blank>血管紧张素Ⅱ受体拮抗剂在冠心病患者中的临床应用建议(2018)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=965761c0015925ab" title="脑卒中合并稳定性冠心病运动康复专家共识" target=_blank>脑卒中合并稳定性冠心病运动康复专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7844e1c0015e81fa" title="冠心病心绞痛介入前后中医诊疗指南" target=_blank>冠心病心绞痛介入前后中医诊疗指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=749651c001569069" title="冠心病稳定型心绞痛中医诊疗专家共识" target=_blank>冠心病稳定型心绞痛中医诊疗专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=69d3d1c0015222d3" title="稳定性冠心病无创影像检查路径的专家共识" target=_blank>稳定性冠心病无创影像检查路径的专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%86%A0%E5%BF%83%E7%97%85" target=_blank>有关冠心病更多指南</a></ul>, tagList=[TagDto(tagId=703, tagName=冠心病), TagDto(tagId=318, tagName=心律失常)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10818, appHits=719, showAppHits=10, pcHits=8123, showPcHits=2773, likes=154, shares=17, comments=3, approvalStatus=1, publishedTime=Sun Sep 30 20:56:34 CST 2018, publishedTimeString=2018-09-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Sep 30 20:56:34 CST 2018, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 20:42:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 SIGN国家临床指南:冠心病心律失常(152))])
2018 SIGN国家临床指南:冠心病心律失常(152)
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1179310, encodeId=5bdd11e931078, content=非常棒的APP, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01af1957237, createdName=1e129e46m43(暂无匿称), createdTime=Fri Dec 31 15:03:15 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883424, encodeId=27ea88342408, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa295416465, createdName=ms7000001941388121, createdTime=Mon Sep 07 22:19:16 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347457, encodeId=cd0b34e4576f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Sep 30 22:44:50 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2021-12-31 1e129e46m43(暂无匿称)

    非常棒的APP

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1179310, encodeId=5bdd11e931078, content=非常棒的APP, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01af1957237, createdName=1e129e46m43(暂无匿称), createdTime=Fri Dec 31 15:03:15 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883424, encodeId=27ea88342408, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa295416465, createdName=ms7000001941388121, createdTime=Mon Sep 07 22:19:16 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347457, encodeId=cd0b34e4576f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Sep 30 22:44:50 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2020-09-07 ms7000001941388121

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1179310, encodeId=5bdd11e931078, content=非常棒的APP, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01af1957237, createdName=1e129e46m43(暂无匿称), createdTime=Fri Dec 31 15:03:15 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883424, encodeId=27ea88342408, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa295416465, createdName=ms7000001941388121, createdTime=Mon Sep 07 22:19:16 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347457, encodeId=cd0b34e4576f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Sep 30 22:44:50 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
    2018-09-30 医者仁心5538

    学习了

    0